- Home
- AMZE vs AYTU Comparison
AMZE vs AYTU Comparison
Compare AMZE & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- AYTU
- Stock Information
- Founded
- AMZE 2019
- AYTU N/A
- Country
- AMZE United States
- AYTU United States
- Employees
- AMZE N/A
- AYTU N/A
- Industry
- AMZE Beverages (Production/Distribution)
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- AMZE Consumer Staples
- AYTU Health Care
- Exchange
- AMZE Nasdaq
- AYTU Nasdaq
- Market Cap
- AMZE 8.8M
- AYTU 8.3M
- IPO Year
- AMZE 2021
- AYTU N/A
- Fundamental
- Price
- AMZE $0.49
- AYTU $1.09
- Analyst Decision
- AMZE
- AYTU
- Analyst Count
- AMZE 0
- AYTU 0
- Target Price
- AMZE N/A
- AYTU N/A
- AVG Volume (30 Days)
- AMZE 357.0K
- AYTU 37.1K
- Earning Date
- AMZE 05-13-2025
- AYTU 05-14-2025
- Dividend Yield
- AMZE N/A
- AYTU N/A
- EPS Growth
- AMZE N/A
- AYTU N/A
- EPS
- AMZE N/A
- AYTU N/A
- Revenue
- AMZE $299,065.00
- AYTU $77,232,000.00
- Revenue This Year
- AMZE N/A
- AYTU N/A
- Revenue Next Year
- AMZE N/A
- AYTU $8.14
- P/E Ratio
- AMZE N/A
- AYTU N/A
- Revenue Growth
- AMZE N/A
- AYTU N/A
- 52 Week Low
- AMZE $0.48
- AYTU $1.15
- 52 Week High
- AMZE $0.62
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- AMZE N/A
- AYTU 33.76
- Support Level
- AMZE N/A
- AYTU $1.20
- Resistance Level
- AMZE N/A
- AYTU $1.29
- Average True Range (ATR)
- AMZE 0.00
- AYTU 0.06
- MACD
- AMZE 0.00
- AYTU 0.00
- Stochastic Oscillator
- AMZE 0.00
- AYTU 0.00
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.